PRACTICAL: Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor

Sponsor
Angela Bianco (Other)
Overall Status
Terminated
CT.gov ID
NCT03423147
Collaborator
Stryker Nordic (Industry)
329
1
2
28.3
11.6

Study Details

Study Description

Brief Summary

Surgical site infections (SSI) are the second most common cause of nosocomial infections accounting for 15% of all nosocomial infections among hospitalized patients and 38% of nosocomial infections in surgical patients. In obstetric patients, infectious morbidity (i.e. SSI, endometritis) occurs in 5-10% of cesarean sections, which is 5-fold higher than vaginal deliveries. Additionally, infectious morbidity is thought to be highest in those patients who have cesarean sections after undergoing labor.

Chlorhexidine, a chemical antiseptic effective on gram positive and gram negative bacteria, reduces skin microflora/colonization but it is not clear if it decreases the risk of SSI.

Historically, chlorhexidine has been studied and used in orthopedic and cardiac implant surgeries. Research on the use of chlorhexidine for SSI prevention in cesarean sections is limited. This study intends to evaluate the effectiveness of use of both chlorhexidine gluconate (CHG) wipe and vaginal scrub in reducing SSI in patients undergoing cesarean section that have previously been laboring. Patients will be randomized to one of two groups: wash with both a pre-operative CHG cloth prior to surgery and chlorhexidine gluconate vaginal scrub in addition to standard preoperative scrub as compared to standard preoperative scrub alone.

Condition or Disease Intervention/Treatment Phase
  • Drug: 2% chlorhexidine gluconate cloth
  • Drug: 4% Chlorhexidine gluconate vaginal scrub
Phase 2

Detailed Description

The study will be offered to women who are admitted to undergo labor at Mount Sinai Medical Center. The eligible women will be randomized to use of a 2% chlorhexidine gluconate (CHG) cloth with 4% chlorhexidine gluconate vaginal scrub (including standard preoperative care prior to cesarean section) or standard preoperative care. Participants will not be blinded to the arm in which they have been assigned.

Researchers will have access to all patients scheduled for delivery at Mount Sinai Medical Center. About 1800 deliveries by cesarean section occur each year at Mount Sinai. Of these, approximately 800 are cesarean sections after failed labor. Assuming a primary outcome rate of 20% in the control arm, a sample size of 329 in each group would give 80% power to detect a 40% reduction in surgical site infection between the active group and control. The aim is to recruit 400 patients per group (for a total of 800 patients) to account for patient drop out or non-compliance.

Sage Products, Inc will be providing the CHG cloths.

This study intends to show that simultaneous use of 2% CHG cloths and 4% CHG vaginal scrub prior to cesarean section will reduce the rate of SSI in women who have previously been laboring.

Study Design

Study Type:
Interventional
Actual Enrollment :
329 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Gluconate Cloth and Chlorhexidine Gluconate Vaginal Scrub Reduces Infectious Morbidity in Patients Undergoing Cesarean Section After Labor
Actual Study Start Date :
Oct 5, 2018
Actual Primary Completion Date :
Feb 11, 2021
Actual Study Completion Date :
Feb 11, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Chlorhexidine gluconate vaginal scrub and cloth

Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section

Drug: 2% chlorhexidine gluconate cloth
applied to their abdomen
Other Names:
  • 2% Chloraprep solution
  • Drug: 4% Chlorhexidine gluconate vaginal scrub
    applied as a vaginal cleanse in the operating room prior to cesarean section

    Active Comparator: Standard Treatment

    Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.

    Drug: 2% chlorhexidine gluconate cloth
    applied to their abdomen
    Other Names:
  • 2% Chloraprep solution
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of surgical site infection [up to 6 weeks postpartum]

      Surgical site infection will be a composite of wound infection and postpartum endometritis. Endometritis is defined as postoperative fever of 100.4 °F or more occurring 24 hours after delivery associated with uterine tenderness and persistent foul-smelling lochia, requiring broad-spectrum intravenous antibiotic administration. Wound infection is defined as erythema or wound edge separation with purulent discharge involving the cesarean incision site that requires antibiotic therapy and wound care.

    Secondary Outcome Measures

    1. Number of maternal complications or interventions [up to 6 weeks postpartum]

    2. Number of neonatal ICU admissions [up to 6 weeks postpartum]

    3. Maternal length of stay [up to 6 weeks postpartum]

    4. Number of readmissions [up to 6 weeks postpartum]

    5. Estimated blood loss [Day 1]

    6. Length of time from incision to delivery [Day 1]

    7. Length of operation [Day 1]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women at > 24 weeks gestation who are admitted in labor or admitted for induction of labor at Mount Sinai Hospital
    Exclusion Criteria:
    • Allergy to chlorhexidine

    • Unplanned or emergency cesarean section

    • Women at <24 weeks gestation

    • Estimated fetal weight <500 grams

    • Fetal face presentation regardless of gestational age.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Icahn School of Medicine at Mount Sinai New York New York United States 10029

    Sponsors and Collaborators

    • Angela Bianco
    • Stryker Nordic

    Investigators

    • Principal Investigator: Angela Bianco, MD, Icahn School of Medicine at Mount Sinai

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Angela Bianco, Professor, Icahn School of Medicine at Mount Sinai
    ClinicalTrials.gov Identifier:
    NCT03423147
    Other Study ID Numbers:
    • GCO 17-1235
    First Posted:
    Feb 6, 2018
    Last Update Posted:
    Feb 17, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Angela Bianco, Professor, Icahn School of Medicine at Mount Sinai
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 17, 2022